Quadrol is an immunostimulant and has been implicated as a potentially useful agent in accelerated wound healing. In Vitro: Results show that viability of macrophages incubated with Quadrol at concentrations of 0.5 mM, 1 mM and 4mM are identical to that for controls. Viability, however, is reduced to 50% of control at concentrations of 16 mM to 32 mM. After four hours, at concentrations of 1 mM and 4 mM, Quadrol produces enhanced spreading of 88% and 80%, respectively, as compared to the control of 28%. Quadrol, at a concentration of 16 mM, shows reduced percentage of spreading of macrophages after four hours. Exposure of macrophages to 1.0 mM or 4.0 mM Quadrol concentrations enhances phagocytic activity, 41% and 57%, respectively, over that of the cells exposed to media alone (34%). In Vivo: On day eight after the implantation, the amount of collagen in the implants of normal mice injected with Quadrol exceeds controls by more than 200% (p<0.025). By day 11, the collagen content increases to over 300% higher than controls (p<0.01) and by the end of two weeks after wounding, the time interval typically required for normal and complete wound healing, the collagen accumulated in the implants of the Quadrol-treated mice is about 50% above control (p<0.1). The accumulation of collagen in the implants of Quadrol treated STZ-diabetic mice about 100% above the untreated diabetic control on days 8 to 11. By day 14, the collagen deposition has increased to 200% above the controls (p<0.0 5).